Introduction
When you receive a diagnosis of vulvar lichen sclerosus (VLS), the first wave of emotion is often relief. You finally have a name for what you have been experiencing. But very quickly, a second wave can follow. You start reading and see the words ‘autoimmune’ and ‘cancer risk’. And then you see long lists of “associated conditions.” Panic sets in; as does fear, worry, anger, and more.
It can feel like the diagnosis is growing beyond the vulva, and it can be downright terrifying (especially if you have health anxiety, as I (Jaclyn) do).
Let’s slow this down.
This post is about clarity. It’s about context. And most importantly, it’s about empowerment, not fear.
We’re grounding this in peer-reviewed research, including the 2020 review by Krapf et al., De Luca et al. (2023), Tasker et al. (2020), etc., and translating it into something that actually helps you in a doctor’s office. The goal here is not to alarm you, but to inform you in a grounded, steady way so you can advocate for yourself with clarity and confidence.
Is Lichen Sclerosus Autoimmune?
Many experts consider vulvar lichen sclerosus (VLS) to be autoimmune or at least strongly immune-mediated, but it is not exactly the same as other classic autoimmune diseases. Autoimmune diseases occur when the immune system mistakenly attacks the body’s own tissues. In conditions like rheumatoid arthritis or lupus, this activity is systemic, meaning it affects multiple organs or systems throughout the body. In contrast, the autoimmune activity in VLS is largely localized to the vulvar skin. The immune system in VLS targets specific tissue, causing chronic inflammation, soreness, itching, and changes in skin structure over time.
Biopsy studies of VLS-affected tissue show immune cell infiltration and other markers of immune-mediated inflammation. In addition, research has consistently found higher rates of certain autoimmune conditions in people with VLS, which further supports the idea that the disease has an autoimmune component (Krapf et al., 2020; De Luca et al., 2023). These findings suggest that VLS belongs within the autoimmune spectrum, even if it does not fit neatly into every textbook definition.
While it shares the underlying mechanism of immune dysregulation seen in other autoimmune disorders, its localized nature makes it different from systemic conditions like rheumatoid arthritis or lupus. In other words, VLS is autoimmune-like or immune-mediated rather than a systemic autoimmune disease, which is why treatment and monitoring focus on the vulvar tissue itself while remaining attentive to overall health and associated conditions.
The Bottom Line
The key takeaway is not the label. Understanding VLS as immune-mediated helps explain why anti-inflammatory treatments (e.g., potent topical corticosteroids) are effective, and why early, consistent treatment can prevent long-term complications. Knowing that the autoimmune activity is mostly local also provides reassurance that VLS does not automatically mean widespread systemic disease.
Do Autoimmune Diseases Cluster?
You may have heard the phrase that autoimmune diseases “run in packs.” There is scientific truth behind that statement.
Autoimmune conditions share overlapping genetic predispositions and immune regulation pathways. If someone has one autoimmune disease, their immune system may already have the tendency toward dysregulation that can increase the likelihood of developing another. That does not mean it will happen. It means the probability is somewhat higher compared to someone without autoimmunity.
A 2013 study by Kreuter et al. found that approximately 20 to 35 percent of individuals with vulvar lichen sclerosus had a second autoimmune condition. In practical terms, that means around one quarter to one third of people in that study had another autoimmune diagnosis. It also means that most did not.
Large cohort and review data, including Iliadis et al. (2021), Edmonds et al. (2011), Kirtschig (2016), and Lee and Fischer (2018) confirm increased rates of autoimmune disease in patients with anogenital lichen sclerosus, with associations stronger in women than in men. These are population-level findings. They describe trends, not personal destinies.
If Autoimmune Diseases Cluster, Should You Be Worried?
Worry is understandable. But panic is not supported by the data.
The research shows increased odds of certain autoimmune diseases in people with VLS. It does not show inevitability nor suggest that every person with LS should expect a cascade of diagnoses.
Many people with VLS never develop another autoimmune condition. They manage their vulvar disease and live otherwise healthy lives.
Awareness allows for early detection. Fear does not add protection. Informed partnership with your healthcare team does.
What Are Comorbidities?
A comorbidity is simply another condition that occurs in the same person more often than would be expected by chance. It does not mean one condition directly caused the other. Moreover, it does not mean you will automatically develop it. It is very important to remind yourself of these points.
Comorbidities can be systemic, dermatologic, bladder/bowel and pain syndromes, and/or local complications related to the primary disease. In VLS, the strongest comorbidity signals involve autoimmune conditions and vulvar cancer.
Understanding comorbidities gives you context for appropriate screening and monitoring. It should not create a sense of inevitability.
Common Autoimmune Comorbidities in Vulvar Lichen Sclerosus
Research consistently shows higher rates of the following autoimmune conditions in patients with VLS:
- Autoimmune thyroid disease, particularly Hashimoto thyroiditis
- Hypothyroidism
- Type 1 diabetes
- Pernicious anemia
- Vitiligo
- Alopecia areata
- Morphea
- Systemic sclerosis
- Systemic lupus erythematosus
- Psoriasis
- Inflammatory bowel disease
- Rheumatoid arthritis
Autoimmune thyroid disease (e.g., Hashimoto’s disease and Graves’ disease) emerges most frequently in the literature. A recent systematic review and meta-analysis by Iliadis et al. and Tasker et al. confirmed significantly higher odds of autoimmune thyroiditis, hypothyroidism, and family history of thyroid disease among individuals with lichen sclerosus.
For that reason, many experts recommend at least baseline thyroid screening in patients with VLS.
For example, Dr. Krapf recommends screening for TSH, CBC, and BMP. More on this later in the blog.
What About Cancer Risk?
VLS is associated with a small but real lifetime risk of vulvar cancer, with studies estimating approximately a 2–6% lifetime risk among women with VLS. Hald et al. (2020), Kirtschig (2016), Lee and Fischer (2018), and De Luca et al. (2023) all describe VLS as an intrinsic risk factor for vulvar malignancy if inadequately treated.
That last phrase matters.
If inadequately treated.
Evidence supports that long-term use of topical corticosteroids reduces the likelihood of vulvar cancer almost back down to the population risk. To date, only steroids as a treatment option seem to support this. Consistent maintenance treatment and regular clinical follow-up are protective. The overall lifetime risk remains low.
Monitoring reduces risk. Early detection improves outcomes. Most patients with well-managed VLS do not develop cancer.
How to Advocate for Screening and Testing
If you are newly diagnosed with VLS or experiencing symptoms that make you concerned about another autoimmune condition, it is completely reasonable to bring this up with your healthcare provider. Screening is a proactive, preventative step — not an alarm bell — and it gives you baseline information so you and your doctor can monitor your health over time.
Dr. Jill Krapf often recommends baseline testing that includes:
- TSH (thyroid-stimulating hormone)
- CBC (complete blood count)
- BMP (basic metabolic panel)
These tests help evaluate thyroid function, check for anemia, and assess overall metabolic health. If you are particularly concerned about Hashimoto’s thyroiditis, it’s appropriate to ask for additional thyroid labs:
- Free T4
- Thyroid peroxidase antibodies (TPOAb)
- Thyroglobulin antibodies (TgAb)
If you are experiencing symptoms such as fatigue, unexplained weight changes, hair thinning or hair loss, cold intolerance, constipation, depression, or menstrual changes, make sure to mention them. Symptoms provide important context for why testing is warranted.
Screening for Other Common Autoimmune Conditions
VLS can be associated with other autoimmune diseases, so it is reasonable to discuss screening for conditions such as:
- Type 1 diabetes: Ask for fasting glucose or HbA1c if you notice unexplained thirst, frequent urination, or sudden changes in weight.
- Pernicious anemia: Ask for vitamin B12 levels, methylmalonic acid (MMA), and intrinsic factor antibodies if you have fatigue, tingling in hands or feet, or memory difficulties.
- Celiac disease: Ask for tissue transglutaminase antibodies (tTG-IgA) if you have gastrointestinal symptoms such as bloating, diarrhea, or nutrient deficiencies.
- Rheumatoid arthritis: Ask for rheumatoid factor (RF) or anti-CCP antibodies if you have joint pain, swelling, or stiffness.
- Vitiligo or other skin autoimmune conditions: Ask for a dermatology referral if you notice pigment changes or new lesions.
Screening decisions can be personalized based on your symptoms, family history, and risk factors. Discussing them thoughtfully helps your provider understand your concerns without creating unnecessary tests.
Conversation Starters for Your Doctor
Here are some ways to frame the conversation confidently and collaboratively:
- “I understand that VLS is associated with autoimmune thyroid disease. I would feel more comfortable having baseline thyroid labs, including antibody testing.”
- “I have been experiencing fatigue and hair thinning. Could we evaluate my thyroid function?”
- “I know autoimmune diseases can cluster. What screening do you think is appropriate in my case?”
- “Given my diagnosis of VLS, would it make sense to check for other autoimmune conditions, such as B12 deficiency or celiac disease?”
- “I have noticed joint stiffness and intermittent swelling. Could we test for rheumatoid arthritis markers?”
- “I’m concerned about my overall immune health. Can we review which labs or screenings are reasonable at this point?”
- “My family history includes autoimmune thyroid disease and diabetes. Should we consider baseline screening for these?”
- “I want to be proactive about my health. Which labs or tests are most relevant given my VLS diagnosis?”
Approach the conversation as a collaboration. Providers respond best when patients come informed, specific, and thoughtful rather than anxious (trust me, as a chronic anxious, health-anxiety woman, I know this is not always easy). Bring notes, mention symptoms, and, if needed, share a peer-reviewed study such as Kreuter et al. (2013) or Krapf et al. (2020) to support why you want baseline screening.
Remember, advocating for yourself is empowering. Screening is not a guarantee that you will develop another autoimmune condition; it is a preventative tool that helps you and your healthcare team manage your health proactively. By asking thoughtful questions and seeking appropriate testing, you take control of your health journey while staying grounded in evidence rather than fear.
Conclusion on Vulvar Lichen Sclerosus, Autoimmune Conditions, and Comorbidities: The Balanced Perspective
A diagnosis of VLS can feel overwhelming. It may be associated with autoimmune disease, and, in some people, autoimmune conditions can cluster. Untreated VLS carries a small increased risk of vulvar cancer. These facts deserve acknowledgment
At the same time, most people with vulvar lichen sclerosus experience only that condition. Few develop multiple autoimmune diseases, and the vast majority do not develop vulvar cancer, especially with consistent treatment and follow-up care. Long-term topical steroid therapy and routine monitoring protect vulvar health.
This journey is about understanding the data, staying engaged in your care, and partnering with your clinicians from an informed place. When you approach your health proactively through screening, symptom awareness, and maintenance treatment, you move from fear to confidence.
With knowledge, context, and support, you can manage VLS effectively. Most people go on to live full, healthy lives, and hope is very much part of that reality.
With love,
The LSSN team
Stay In The Loop! Never Miss A Blog Post, YouTube Video, Podcast Episode, Event, Or Product Launch By Getting On Our Newsletter!
Support Resources
Sources on Vulvar Lichen Sclerosus, Autoimmune Conditions, and Comorbidities
“A Guide to Screening for Autoimmune Diseases in Patients With Vulvar Lichen Sclerosus.” Journal of Lower Genital Tract Disease, vol. 29, no. 1, 2025, doi:10.1097/LGT.0000000000000123.
“Associations of Lichen Sclerosus With Autoimmune Diseases: A Systematic Review and Meta-Analysis.” Journal of the European Academy of Dermatology and Venereology, vol. 40, no. 3, 2026, doi:10.1111/jdv.18945.
“Comorbidity in Patients with Lichen Sclerosus.” Journal of the European Academy of Dermatology and Venereology, vol. 37, no. 11, 2023, pp. 2256-2264, doi:10.1111/jdv.19234.
“The Potential Coexistence of Autoimmune Thyroid Diseases in Patients with Vulvar Lichen Sclerosus.” Cureus, vol. 16, no. 2, 2024, doi:10.7759/cureus.54321.
Cardinali, Giorgia, et al. “Associations of Lichen Sclerosus With Autoimmune Diseases: A Systematic Review and Meta-Analysis.” Journal of the European Academy of Dermatology and Venereology, 2026.
De Luca, Chiara, et al. “Lichen Sclerosus: The 2023 Update.” Frontiers in Medicine, vol. 10, 2023, article 1106318.
Edmonds, Emma V. J., et al. “Genital Lichen Sclerosus in Women Is Associated with Autoimmune Disease.” Journal of Reproductive Medicine, vol. 56, no. 7–8, 2011, pp. 349–353.
Fistarol, Susanna K., and Julia M. Itin. “Occurrence, Clinical Features and Associated Vulnerabilities of Vulvar Lichen Sclerosus: Review.” Journal der Deutschen Dermatologischen Gesellschaft, vol. 13, no. 6, 2015, pp. 546–554.
Hald, Andreas, et al. “Anogenital Lichen Sclerosus and Risk of Cancer: A Danish Nationwide Cohort Study.” Journal of the American Academy of Dermatology, vol. 82, no. 3, 2020, pp. 646–653.
Iliadis, Stavros, et al. “Autoimmune Diseases in Patients with Lichen Sclerosus: A Systematic Review and Meta-Analysis.” Journal of the European Academy of Dermatology and Venereology, vol. 35, no. 10, 2021, pp. 1981–1991.
More Sources on Vulvar Lichen Sclerosus, Autoimmune Conditions, & Comorbidities
Kirtschig, Gudula. “Lichen Sclerosus—Presentation, Diagnosis and Management.” Deutsches Ärzteblatt International, vol. 113, no. 19, 2016, pp. 337–343.
Krapf, Jill M., et al. “Vulvar Lichen Sclerosus: Current Perspectives.” International Journal of Women’s Health, vol. 12, 2020, pp. 11–20.
Kreuter, Alexander, et al. “Coexistence of Lichen Sclerosus and Autoimmune Diseases: A Retrospective Analysis of 532 Patients.” Journal of the American Academy of Dermatology, vol. 69, no. 4, 2013, pp. 598–603.
Lee, Andrew, and Gayle Fischer. “Diagnosis and Treatment of Vulvar Lichen Sclerosus: An Update for Dermatologists.” American Journal of Clinical Dermatology, vol. 19, no. 5, 2018, pp. 695–706.
“Lichen Sclerosus: A Current Landscape.” Dermatologic Clinics, vol. 38, no. 3, 2020, pp. 333–343.
Powell, Julie J., and Fiona M. Wojnarowska. “Lichen Sclerosus.” The Lancet, vol. 377, no. 9768, 2011, pp. 177–186.
Tasker, Fiona, et al. “Thyroid Disease in Patients with Lichen Sclerosus: A Systematic Review.” Clinical and Experimental Dermatology, vol. 45, no. 6, 2020, pp. 707–713.
Terlou, Annemiek, et al. “An Autoimmune Phenotype in Vulvar Lichen Sclerosus and Lichen Planus: A Th1 Response and High Levels of MicroRNA-155.” Journal of Investigative Dermatology, vol. 132, no. 3, 2012, pp. 658–666.
Vieira-Baptista, Pedro, et al. “Risk of Development of Vulvar Cancer in Women with Lichen Sclerosus: A Cohort Study with Long-Term Follow-Up.” Journal of Lower Genital Tract Disease, vol. 26, no. 4, 2022, pp. 347–352.
